Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −0.5x | −0.3x | |
PEG Ratio | −0.03 | 0.02 | 0.00 | |
Price/Book | 0.7x | 1.9x | 2.6x | |
Price / LTM Sales | 7.0x | 3.7x | 2.8x | |
Upside (Analyst Target) | - | 169.6% | 64.7% | |
Fair Value Upside | Unlock | 15.3% | 9.6% | Unlock |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.